Multicenter, Retrospective GUIDANCE001 Study Comparing Transarterial Chemoembolization with or Without Tyrosine Kinase and Immune Checkpoint Inhibitors As Conversion Therapy to Treat Unresectable Hepatocellular Carcinoma: Survival Benefit in Intermediate or Advanced, but Not Early, Stages.

Da-Long Yang,Lin Ye, Fan-Jian Zeng, Jie Liu, Hong-Bing Yao, Jun-Liang Nong, Shao-Ping Liu,Ning Peng, Wen-Feng Li,Pei-Sheng Wu, Chuang Qin, Ze Su, Jun-Jie Ou,Xiao-Feng Dong,Yi-He Yan,Teng-Meng Zhong,Xian-Shuang Mao,Ming-Song Wu, Yao-Zhi Chen, Guo-Dong Wang, Mian-Jing Li, Xue-Yao Wang,Fu-Quan Yang,Yong-Rong Liang, Shu-Chang Chen,Yong-Yu Yang,Kang Chen, Fu-Xin Li, Yong-Cheng Lai, Qing-Qing Pang,Xiu-Mei Liang,Xue-Mei You,Bang-De Xiang, Ya-Qun Yu,Liang Ma,Jian-Hong Zhong

HEPATOLOGY（2025）

引用 0|浏览8

关键词

conversion therapy,HCC,immune checkpoint inhibitors,transarterial chemoembolization,tyrosine kinase inhibitors,unresectable

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要